Key points are not available for this paper at this time.
This study focuses on addressing the challenges associated with doxorubicin (DOX), an anthracycline chemotherapeutic widely used in cancer treatment. Despite its efficacy, DOX is linked to severe side effects that limit its clinical applications. Novel pharmaceutical formulations aim to mitigate these issues, providing better safety profiles. The development of these formulations requires analytical methods that can accurately and quickly quantify DOX. A cost-effective and portable electrochemical sensor for DOX detection was developed utilizing in-house printed carbon electrodes decorated with gold nanoparticles. DOX was detected using differential pulse voltammetry. The sensor demonstrated an accurate quantification of DOX from novel pharmaceutical formulations and serum, presenting a dynamic range of 1 to 500 μg/mL and a low detection limit of 0.3 μg/mL. The method, successfully applied to characterize DOX-loaded nanosomes, offers a valuable alternative in the early stages of formulation development, reducing costs and saving time, while maintaining accuracy.
Pusta et al. (Fri,) studied this question.